Literature DB >> 1487546

Effects of meals and meal composition on the bioavailability of fenretinide.

D R Doose1, F L Minn, S Stellar, R K Nayak.   

Abstract

The effects of meals and meal composition on the bioavailability of fenretinide, N-(4-hydroxyphenyl) retinamide, a synthetic retinoid undergoing clinical trials, were examined in two separate studies using an open, randomized, crossover design. In the first study, 13 healthy male volunteers received 300-mg doses of fenretinide (1) while fasting and (2) after a high-fat breakfast. In a subsequent study, 15 subjects received 300 mg fenretinide after each of three different test meals (high-fat, high-protein, and high-carbohydrate) separated by a 1-week washout period. Plasma specimens obtained over a 72-hour period after each treatment were assayed by high-pressure liquid chromatography to characterize the effects of a meal and meal composition on the bioavailability of fenretinide. Results from the initial study demonstrated a significant increase in the bioavailability of fenretinide after a high-fat meal. In the follow-up study, the bioavailability of fenretinide, as assessed by total area under the plasma concentration curve, was three times greater after the high-fat meal than after the high-carbohydrate meal. This supported the findings of the first study. Although to a lesser extent, the high-protein meal also produced a greater area under the curve than the high-carbohydrate meal. These combined findings demonstrate that the bioavailability of fenretinide is markedly influenced not only by administration with meals but also by the specific composition of such meals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1487546

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.

Authors:  Judith G Villablanca; Wendy B London; Arlene Naranjo; Patrick McGrady; Matthew M Ames; Joel M Reid; Renee M McGovern; Sarah A Buhrow; Hollie Jackson; Enno Stranzinger; Brenda J Kitchen; Paul M Sondel; Marguerite T Parisi; Barry Shulkin; Gregory A Yanik; Susan L Cohn; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-09       Impact factor: 12.531

4.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

5.  Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.

Authors:  Vinay K Puduvalli; W K Alfred Yung; Kenneth R Hess; John G Kuhn; Morris D Groves; Victor A Levin; James Zwiebel; Susan M Chang; Timothy F Cloughesy; Larry Junck; Patrick Wen; Frank Lieberman; Charles A Conrad; Mark R Gilbert; Christina A Meyers; Vivien Liu; Minesh P Mehta; M Kelly Nicholas; Michael Prados
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.

Authors:  G A Otterson; J Lavelle; M A Villalona-Calero; M Shah; X Wei; K K Chan; B Fischer; M Grever
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

8.  Effects of food on the relative bioavailability of lapatinib in cancer patients.

Authors:  Kevin M Koch; Nandi J Reddy; Roger B Cohen; Nancy L Lewis; Bonnie Whitehead; Kathleen Mackay; Andrew Stead; Andrew P Beelen; Lionel D Lewis
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

9.  A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

Authors:  C L O'Bryant; C H Lieu; S Leong; R Boinpally; M Basche; L Gore; K Leonardi; M K Schultz; S Hariharan; L Chow; S Diab; A Gibbs; S G Eckhardt
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

Review 10.  Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?

Authors:  Massimiliano Cazzaniga; Clara Varricchio; Chiara Montefrancesco; Irene Feroce; Aliana Guerrieri-Gonzaga
Journal:  J Biomed Biotechnol       Date:  2012-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.